Table 1.
Baseline clinical characteristics of patients (n = 11).
| Characteristics | No. of patients (%) |
|---|---|
| Age, median, years (range) | 56.6 (43–71) |
| Gender | |
| Male | 10 (90.9) |
| Female | 1 (9.1) |
| ECOG performance status | |
| 0 | 2 (18.2) |
| 1 | 9 (81.8) |
| Child-Pugh class | |
| A | 9 (81.8) |
| B | 2 (18.2) |
| BCLC stage | |
| B | 6 (54.5) |
| C | 5 (45.5) |
| Tumor size | |
| <5 cm | 4 (36.4) |
| 5–10 cm | 4 (36.4) |
| ≥ 10 cm | 3 (27.3) |
| Number of tumors | |
| 2-5 | 3 (27.3) |
| ≥ 5 | 5 (45.5) |
| ≥ 10 | 3 (27.3) |
| Macrovascular invasion | |
| Yes | 5 (45.5) |
| No | 6 (54.5) |
| Etiology | |
| HBV/HCV/unknown | 6 (54.5)/3 (27.3)/2 (18.2) |
| Extra-hepatic spread | |
| present/absent | 0 (0.0)/11 (100) |
| Prior therapies | |
| Surgery plus TACE | 4 (36.4) |
| Surgery plus RT | 1 (9.1) |
| TACE plus sorafenib | 1 (9.1) |
| TACE alone | 3 (27.3) |
| No | 2 (18.2) |
| Morphology of HCC | |
| Multinodular | 8 (72.7) |
| Infiltrative | 3 (27.3) |
| α-fetoprotein | |
| ≥ 400 μg/L | 6 (54.5) |
| < 400 μg/L | 5 (45.5) |
BCLC, Barcelona clinic liver cancer; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; TACE, transarterial chemoembolization; RT, radiotherapy.